Drug · DIN 02456869
KEYTRUDA
FOR I.V. INFUSION. 4 ML SINGLE-USE VIAL
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since July 13, 2017; first marketed July 13, 2017.
- Drug Identification Number (DIN)
- 02456869
- Company (DIN owner)
- Merck Canada IncKirkland, Quebec, Canada
- Schedule
- Schedule d; Prescription
- Dosage form
- Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Pembrolizumab L01FF02
- Class
- Human
- Record last updated
- August 13, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| PEMBROLIZUMAB | 25 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- August 9, 2016: NOC 18345Supplement to a New Drug Submission (SNDS) · Alternate drug substance manufacturing and test site; additional drug product manufacturing facility; new dosage form
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “keytruda”. A notice may cover another product or only some lots: read it to see what it covers.
- Keytruda (2019-04-23)April 23, 2019 · Drugs · Product safety · Type III
Other DINs named KEYTRUDA
- DIN 02441152 · Cancelled Post Market